BGLC
Income statement / Annual
Last year (2023), BioNexus Gene Lab Corp.'s total revenue was $9.77 M,
a decrease of 10.60% from the previous year.
In 2023, BioNexus Gene Lab Corp.'s net income was -$2.63 M.
See BioNexus Gene Lab Corp.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$9.77 M
|
$10.93 M
|
$13.36 M
|
$11.39 M
|
$126,955.00
|
$212,328.00
|
$107,680.00
|
$0.00
|
Cost of Revenue |
$8.44 M |
$9.67 M |
$11.17 M |
$9.67 M |
$71,067.00 |
$183,563.00 |
$28,871.00 |
$0.00 |
Gross Profit |
$1.33 M |
$1.26 M |
$2.19 M |
$1.72 M |
$55,888.00 |
$28,765.00 |
$78,809.00 |
$0.00 |
Gross Profit Ratio |
0.14 |
0.12 |
0.16 |
0.15 |
0.44 |
0.14 |
0.73 |
0 |
Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
General & Administrative
Expenses |
$4.41 M
|
$1.73 M
|
$1.20 M
|
$1.33 M
|
$356,641.00
|
$241,930.00
|
$0.00
|
$0.00
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$4.41 M
|
$1.73 M
|
$1.20 M
|
$1.33 M
|
$356,641.00
|
$241,930.00
|
$206,715.00
|
$835.00
|
Other Expenses |
$0.00 |
-$179,283.00 |
-$66,491.00 |
-$886,942.00 |
-$25,048.00 |
$273,066.00 |
$0.00 |
$0.00 |
Operating Expenses |
$3.92 M |
$1.55 M |
$1.14 M |
$446,001.00 |
$331,593.00 |
-$31,136.00 |
$206,715.00 |
$835.00 |
Cost And Expenses |
$12.36 M |
$11.22 M |
$12.31 M |
$10.12 M |
$402,660.00 |
$152,427.00 |
$235,586.00 |
$835.00 |
Interest Income |
$0.00 |
$12,479.00 |
$12,973.00 |
$11,313.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$13,929.00 |
$12,479.00 |
$12,973.00 |
$11,313.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$108,423.00
|
$105,419.00
|
$108,215.00
|
$101,603.00
|
$53,332.00
|
$40,611.00
|
$15,031.00
|
$835.00
|
EBITDA |
-$2.49 M
|
-$185,758.00
|
$1.16 M
|
$1.38 M
|
-$222,373.00
|
$100,512.00
|
-$112,880.00
|
-$840.00
|
EBITDA Ratio |
-0.25 |
-0.02 |
0.09 |
0.12 |
-1.75 |
0.47 |
-1.05 |
0 |
Operating Income Ratio
|
-0.27
|
-0.03
|
0.08
|
0.11
|
-2.17
|
0.28
|
-1.19
|
0
|
Total Other
Income/Expenses Net |
-$35,455.00
|
-$12,479.00
|
-$12,973.00
|
-$11,313.00
|
$25,048.00
|
$273,066.00
|
$8,496.00
|
$5.00
|
Income Before Tax |
-$2.61 M |
-$303,656.00 |
$1.04 M |
$1.26 M |
-$275,705.00 |
$59,901.00 |
-$119,414.00 |
-$835.00 |
Income Before Tax Ratio
|
-0.27
|
-0.03
|
0.08
|
0.11
|
-2.17
|
0.28
|
-1.11
|
0
|
Income Tax Expense |
$21,526.00 |
$52,310.00 |
$291,283.00 |
$168,411.00 |
-$29,236.00 |
$33,447.00 |
$4,336.00 |
-$835.00 |
Net Income |
-$2.63 M |
-$355,966.00 |
$751,571.00 |
$1.09 M |
-$246,469.00 |
$26,454.00 |
-$123,750.00 |
-$835.00 |
Net Income Ratio |
-0.27 |
-0.03 |
0.06 |
0.1 |
-1.94 |
0.12 |
-1.15 |
0 |
EPS |
-0.17 |
-0.0247 |
0.0527 |
0.13 |
-0.0342 |
0.0048 |
-0.0199 |
-0.0001 |
EPS Diluted |
-0.17 |
-0.0247 |
0.0527 |
0.13 |
-0.0342 |
0.0048 |
-0.0199 |
-0.0001 |
Weighted Average Shares
Out |
$15.88 M
|
$14.41 M
|
$14.27 M
|
$8.58 M
|
$7.20 M
|
$5.53 M
|
$6.22 M
|
$6.22 M
|
Weighted Average Shares
Out Diluted |
$15.88 M
|
$14.41 M
|
$14.27 M
|
$8.58 M
|
$7.20 M
|
$5.53 M
|
$6.22 M
|
$6.22 M
|
Link |
|
|
|
|
|
|
|
|